- Supported exchanges /
- NASDAQ /
- ARTV.NASDAQ
Artiva Biotherapeutics, Inc. Common Stock (ARTV NASDAQ) stock market data APIs
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.
Artiva Biotherapeutics, Inc. Common Stock Financial Data Overview
| 12.48 | |
| 11.6148 | |
| - | |
| 12.43 | |
| 11.6148 | |
| 9.68-17.31 | |
| 287 M | |
| 24 289 K | |
| 2 601 K | |
| -0.8729 | |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Artiva Biotherapeutics, Inc. Common Stock Fundamental Data is available in our Financial Data APIs
- Net Revenue 2 601 K
- EBITDA -58 574 000
- Earnings Per Share -2.48
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get Artiva Biotherapeutics, Inc. Common Stock Earnings via APIs
- Latest Release 2024-11-13
- EPS/Forecast -0.635
Get Artiva Biotherapeutics, Inc. Common Stock End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
